Synthace bags US$35m for R&D cloud platform
London-based Synthace, which develops software to automate biology experimentation, has raised US$35m in a Series C from notable investors.
Synthace has developed an R&D platform which can enable scientists to automate experiments as well as sharing their results world-wide. This cloud platform promises to simplify and speed up development as well as improve reproducibility. Synthaces R&D cloud platform is helping life scientists completely change the way they develop new cures and therapeutics to solve humanitys most pressing problems, said CEO Guy Levy-Yurista. Their platform, Synthase believes, will lower the barriers to medical development by keeping up with accelerating innovation and reducing development costs.
The US$35m raised will go towards the companys growth strategy. To maximise impact, we need to expand access and reach to customers across the globe – at scale, added Levy-Yurista.
Among the investors were Horizons Ventures and Sofinnova Partners.
Biocytogen Co Ltd
Draupnir Bio ApS